Doctor profile · Federal record

Dr. Amber Flaherty, M.D.

Medical Oncology Physician (CMS: Medical Oncology) · Phoenix, AZ

  • NPI 1093008336
  • Accepts Medicare
  • MIPS 75.0 / 100 · 2023
  • 18 yrs in practice
  • Female
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
11209 N Tatum Blvd Ste B200
Phoenix, AZ 850283091
(480) 530-4200
fax (833) 456-1459
Mailing address
9535 E Via Montoya
Scottsdale, AZ 852555014

Credentials & registration

NPPES · NUCC
NPI registered
May 2011 — 15 yrs on file
Profile last updated
September 11, 2023
Year of graduation
2008 — 18 yrs since
Specialty taxonomy
207RX0202X — NUCC code
State license (1)
Arizona #50181
Medicaid
AZ #017816

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1093008336. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
35,253
Distinct HCPCS
10
Medicare allowed
$1,081,915
HCPCS Description Services Patients Avg allowed
J0897 Injection, denosumab, 1 mg 10,980 37 $23
J9271 Injection, pembrolizumab, 1 mg 10,800 17 $54
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) 6,630 12 $1
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units 2,000 12 $7
J1100 Injection, dexamethasone sodium phosphate, 1 mg 900 30 $0
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 728 235 $8
J2469 Injection, palonosetron hcl, 25 mcg 610 21 $1
99214 Established patient office or other outpatient visit, 30-39 minutes 441 136 $123
99213 Established patient office or other outpatient visit, 20-29 minutes 350 186 $86
J9217 Leuprolide acetate (for depot suspension), 7.5 mg 286 36 $166

In context: peer comparison

Among 4 peers in this city , average services per provider: 977. This provider delivers 36× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$4,418
Transactions
142
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Merck Sharp & Dohme LLC 16 $430.41
PFIZER INC. 20 $364.11
Daiichi Sankyo Inc. 16 $337.23
AstraZeneca Pharmaceuticals LP 15 $325.48
Janssen Biotech, Inc. 12 $236.75
Novartis Pharmaceuticals Corporation 11 $209.41
Celgene Corporation 9 $194.74
E.R. Squibb & Sons, L.L.C. 8 $192.74
ABBVIE INC. 9 $154.58
Takeda Pharmaceuticals U.S.A., Inc. 6 $140.56
GENZYME CORPORATION 5 $123.06
Eisai Inc. 6 $121.11
Sumitomo Pharma America, Inc. 1 $112.91
Lilly USA, LLC 4 $106.52
SpringWorks Therapeutics, Inc. 4 $104.99

By nature of payment

Food and Beverage
$4,343
Education
$75

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
849
Patients
231
Total drug cost
$1,241,856
Drug Type Claims Patients Total cost
Oxycodone Hcl Generic 125 24 $4,612
Abiraterone Acetate Generic 116 21 $195,961
Prednisone Generic 80 32 $815
Xtandi (Enzalutamide) Brand 74 0 $605,338
Eliquis (Apixaban) Brand 60 19 $79,058
Ondansetron Odt (Ondansetron) Brand 59 33 $1,182
Anastrozole Generic 48 18 $1,549
Lorazepam Generic 43 19 $629
Prochlorperazine Maleate Generic 40 19 $686
Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) Brand 38 14 $1,901

Hospital affiliations

CMS Hospital Compare

Frequently asked questions

Auto-generated from federal data
What is Dr. Amber Flaherty's medical specialty?
Dr. Amber Flaherty practices Medical Oncology Physician in Phoenix, AZ.
Where does Dr. Amber Flaherty practice?
Dr. Amber Flaherty practices at 11209 N Tatum Blvd Ste B200, Phoenix, AZ 850283091. Office phone: 4805304200.
What is Dr. Amber Flaherty's NPI?
Dr. Amber Flaherty's National Provider Identifier (NPI) is 1093008336, issued by NPPES.
Does Dr. Amber Flaherty accept Medicare assignment?
Yes. Dr. Amber Flaherty accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Amber Flaherty commonly perform?
Top Medicare-reported procedures in 2023: Injection, denosumab, 1 mg (HCPCS J0897); Injection, pembrolizumab, 1 mg (HCPCS J9271); Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138). Source: CMS Medicare Physician & Other Practitioners file.